Lanreotide acetate BIM 23014 acetate|cas:2378114-72-6|西域试剂

Lanreotide acetate BIM 23014 acetate,99.92%

产品编号：Bellancom-P1959A| CAS NO：2378114-72-6| 分子式：C₅₆H₇₃N₁₁O₁₂S₂| 分子量：1156.38

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P1959A		￥750.00	杭州北京（现货）
Bellancom-P1959A		￥1300.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Lanreotide acetate BIM 23014 acetate

产品介绍

Lanreotide (BIM 23014) acetate 是一种具有抗肿瘤活性的生长抑素类似物。Lanreotide acetate 可用于类癌综合症的研究。

生物活性

Lanreotide (BIM 23014) acetate is a somatostatin analogue with antineoplastic activity. Lanreotide acetate can be used for the research of carcinoid syndrome.

体外研究

Lanreotide (BIM 23014) (100 nM; 0-48 h) enhanced radiation-induced apoptosis.
Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC₅₀ is 57 nM.
Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	GH3
Concentration:	100 nM
Incubation Time:	48 h, 24 h, or immediately (0 h) before radiation
Result:	Increased apoptotic sub-G1 proportion compared with radiation alone.

体内研究
(In Vivo)

Lanreotide acetate (2.5-10mg/kg; s.c.; daily for 5 days) resluts in tumor growth inhibition.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)
Dosage:	2.5, 5, 10 mg/kg
Administration:	Subcutaneous; daily for 5 days
Result:	Produced tumor growth inhibition.

体内研究

Lanreotide acetate (2.5-10mg/kg; s.c.; daily for 5 days) resluts in tumor growth inhibition.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)
Dosage:	2.5, 5, 10 mg/kg
Administration:	Subcutaneous; daily for 5 days
Result:	Produced tumor growth inhibition.

体内研究

Lanreotide acetate (2.5-10mg/kg; s.c.; daily for 5 days) resluts in tumor growth inhibition.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)
Dosage:	2.5, 5, 10 mg/kg
Administration:	Subcutaneous; daily for 5 days
Result:	Produced tumor growth inhibition.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (86.48 mM; Need ultrasonic)

H₂O : 25 mg/mL (21.62 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.8648 mL	4.3238 mL	8.6477 mL
5 mM	0.1730 mL	0.8648 mL	1.7295 mL
10 mM	0.0865 mL	0.4324 mL	0.8648 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (2.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.16 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.16 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.16 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.16 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。